Related Experiment Video

Updated: Jul 16, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

[Update on antithrombotic treatments in arterial diseases]

P Fontana1

  • 1Service d'angiologie et d'hémostase, Département de médecine interne, Faculté de médecine et HUG, Genève. pierre.fontana@medecine.unige.ch

Revue Medicale Suisse
|March 21, 2007
PubMed

Insights

Arterial diseases often involve atherothrombosis. This review examines antithrombotic agents, including anticoagulants and antiplatelet drugs, for managing these conditions and discusses pending questions on treatment tailoring and duration.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Arterial diseases frequently stem from atherothrombosis, leading to organ or limb ischemia.
  • Antithrombotic agents are crucial for managing atherothrombotic pathology.

Purpose of the Study:

  • To review the indications of current antithrombotic agents in arterial diseases of atherothrombotic origin.
  • To address pending questions regarding treatment tailoring and duration of antiplatelet therapy.

Main Methods:

  • Literature review of current antithrombotic agents.
  • Focus on agents used for atherothrombotic arterial diseases.

Main Results:

  • Overview of available antithrombotic agents: anticoagulants and four classes of antiplatelet drugs (aspirin, thienopyridines, dipyridamole, anti-GPIIbIIIa molecules).
  • Highlights ongoing debates on personalized treatment strategies and optimal therapy duration.

Conclusions:

  • Current antithrombotic therapies are essential but require further refinement.
  • Future research should focus on optimizing treatment selection and duration based on clinical presentation to improve outcomes in atherothrombotic arterial diseases.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...